CA2138644A1 - Method of treating ophthalmic disorders using tgf-.beta. - Google Patents

Method of treating ophthalmic disorders using tgf-.beta.

Info

Publication number
CA2138644A1
CA2138644A1 CA002138644A CA2138644A CA2138644A1 CA 2138644 A1 CA2138644 A1 CA 2138644A1 CA 002138644 A CA002138644 A CA 002138644A CA 2138644 A CA2138644 A CA 2138644A CA 2138644 A1 CA2138644 A1 CA 2138644A1
Authority
CA
Canada
Prior art keywords
tgf
beta
retinal
neovascularization
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002138644A
Other languages
English (en)
French (fr)
Inventor
Bert M. Glaser
George A. Ksander
Bruce B. Pharriss
Ann F. Hanham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2138644A1 publication Critical patent/CA2138644A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002138644A 1992-07-08 1993-07-08 Method of treating ophthalmic disorders using tgf-.beta. Abandoned CA2138644A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91083492A 1992-07-08 1992-07-08
US07/910,834 1992-07-08
US877893A 1993-01-22 1993-01-22
US08/008,778 1993-01-22

Publications (1)

Publication Number Publication Date
CA2138644A1 true CA2138644A1 (en) 1994-01-20

Family

ID=26678611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002138644A Abandoned CA2138644A1 (en) 1992-07-08 1993-07-08 Method of treating ophthalmic disorders using tgf-.beta.

Country Status (5)

Country Link
EP (1) EP0651650A4 (ja)
JP (1) JPH08502033A (ja)
AU (1) AU4668193A (ja)
CA (1) CA2138644A1 (ja)
WO (1) WO1994001124A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
WO1995009004A1 (en) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
AU7846794A (en) * 1993-09-29 1995-04-18 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
WO1998024468A1 (en) * 1996-12-04 1998-06-11 Clark Abbot F TGFα FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
EP1066382A1 (en) * 1997-07-23 2001-01-10 Brigham & Women's Hospital, Inc. Lens epithelial cell derived growth factor
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
ES2211197T3 (es) * 1998-11-23 2004-07-01 Novartis Ag Uso de derivados de estaurosporina para tratar enfermedades neovasculares oculares.
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
WO2001056606A1 (fr) * 2000-01-31 2001-08-09 Santen Pharmaceutical Co., Ltd. Remedes pour troubles ophtalmiques
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
RU2540504C1 (ru) * 2013-12-26 2015-02-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития поздней отслойки сетчатки у детей с рубцовой ретинопатией недоношенных
WO2015142855A1 (en) * 2014-03-17 2015-09-24 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
EP3413851B1 (en) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Packaging
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CA3072847A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8532691A (en) * 1990-08-01 1992-03-02 Chiron Ophthalmics Inc. Method for treating corneal endothelial wounds

Also Published As

Publication number Publication date
EP0651650A1 (en) 1995-05-10
EP0651650A4 (en) 1996-04-17
JPH08502033A (ja) 1996-03-05
WO1994001124A1 (en) 1994-01-20
AU4668193A (en) 1994-01-31

Similar Documents

Publication Publication Date Title
US5767079A (en) Method of treating ophthalmic disorders using TGF -β
CA2138644A1 (en) Method of treating ophthalmic disorders using tgf-.beta.
Glaser et al. Transforming growth factor-β2 for the treatment of full-thickness macular holes: a prospective randomized study
Nuyts et al. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony
Shields et al. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C
Mermoud et al. Surgical management of post-traumatic angle recession glaucoma
RU2674148C2 (ru) Ускоренное заживление повреждений глаз с помощью ангиотензиновых пептидов
CN102633863B (zh) 抗分泌因子对于治疗高眼压的应用
WO1996009838A1 (en) METHOD OF TREATING MACULAR DEGENERATION USING TGF-$g(b)
US6124259A (en) Method for treating ophthalmic disorders with IGFBP
Ruparelia et al. Multiple XEN gel stents for refractory pediatric glaucoma
Buxton et al. Results of penetrating keratoplasty in the iridocorneal endothelial syndrome
JPH08503968A (ja) 増殖因子と代謝拮抗物質を含有する組成物
KR20010012787A (ko) 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의제조에 있어서의 히알루로니다제의 용도
Shingleton et al. Combined phacoemulsification, intraocular lens implantation, and trabeculectomy with a modified scleral tunnel and single-stitch closure
Bruno et al. Subconjunctival placement of human amniotic membrane during high risk glaucoma filtration surgery
Glasser et al. Necrotizing scleritis of scleral flaps after transscleral suture fixation of an intraocular lens
RU2730975C1 (ru) Способ лечения эндотелиально-эпителиальной дистрофии роговицы
Carlson et al. Reduced vision secondary to pigmented cellular membranes on silicone intraocular lenses
GOLDBERG Management of uncontrolled glaucoma with the Molteno system
EP1161256B1 (en) Use of nerve growth factor for the manufacture of a medicament for therapy of intraocular tissue pathologies
Takahashi et al. Antiproliferative effect of retinoic acid in 1% sodium hyaluronate in an animal model of PVR
Kitazawa et al. Surgery for refractory glaucoma
Mandal Endocapsular surgery and capsular bag fixation of intraocular lenses in phacolytic glaucoma
Egrilmez et al. Glaucoma implant surgery with autogenous fascia lata in scleromalacia perforans

Legal Events

Date Code Title Description
FZDE Dead